Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 55 cents for the fourth quarter of 2023, up 22.2% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 7.8% and also exceeded the company’s adjusted earnings per share guidance range of 49-52 cents.The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructuring-related charges, among others.Reported EPS for the fourth quarter ...

Boston Scientific Corporation (NYSE:BSX) Q4 2023 Earnings Conference Call January 31, 2024 8:00 AM ET Company Participants Lauren Tengler - Vice President, Investor Relations Michael Mahoney - Chairman and Chief Executive Officer Daniel Brennan - Executive Vice President and Chief Financial Officer Kenneth Stein - Senior Vice President, Global Chief Medical Officer Jon Monson - Global Controller and Chief Accounting Officer Janarthanan Sathananthan - Chief Medical Officer Conference Call Participants Robert ...

For the quarter ended December 2023, Boston Scientific (BSX) reported revenue of $3.73 billion, up 14.9% over the same period last year. EPS came in at $0.55, compared to $0.45 in the year-ago quarter.The reported revenue represents a surprise of +3.77% over the Zacks Consensus Estimate of $3.59 billion. With the consensus EPS estimate being $0.51, the EPS surprise was +7.84%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Boston Scientific Corp.’s stock BSX, +0.18% jumped 5.8% early Wednesday, after it beat estimates for the fourth quarter and offered upbeat guidance for 2024. The Marlborough, Mass.-based medical technology company posted net income of $504 million, or 34 cents a share, for the quarter, up from $126 million, or 9 cents a share, in the year-earlier period. Excluding special items, the company had EPS of 55 cents, ahead of the 51 cent FactSet consensus. Sales rose 14.9% to $3.725 billion, well ahead of the $3 ...

MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago a ...

In its upcoming report, Boston Scientific (BSX) is predicted by Wall Street analysts to post quarterly earnings of $0.51 per share, reflecting an increase of 13.3% compared to the same period last year. Revenues are forecasted to be $3.59 billion, representing a year-over-year increase of 10.7%.The current level reflects an upward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their ini ...

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis o ...

Boston Scientific Corporation (BSX) is scheduled to report fourth-quarter and full-year 2023 results on Jan 31, before the opening bell.In the last reported quarter, the company’s earnings per share of 50 cents exceeded the Zacks Consensus Estimate by 4.2%. BSX’s bottom line beat estimates in three of the trailing four quarters and missed on one occasion. The company has a trailing four-quarter earnings surprise of 4.34% on average.Factors at PlayWith U.S. hospitals reporting an increase in the number of pr ...

智通财经APP获悉，投行Baird表示，在经历了三年的表现不佳之后，预计医疗科技股将在2024年跑赢大盘，但对牙科和美容市场近期仍持谨慎态度。 这家投行指出，上周在旧金山举行的投资会议提振了医疗科技股，iShares US Medical Devices ETF在过去五天里上涨了2.8%，超过了标准普尔500指数1.6%的涨幅。 Baird对2024年医疗科技股的首选仍然是爱尔康(ALC.US)、史赛克(SYK.US)、库珀医疗(COO.US)、Axonics(AXNX.US)和波士顿科学(BSX.US)。 Baird在最近的一份报告中表示，医疗技术患者数量在第四季度似乎保持良好，尤其是髋关节/膝关节置换术、糖尿病设备、隐形眼镜、眼科产品、心血管和神经调节设备以及手术机器人的需求强劲。Baird在最近的一份报告中表示，提前公布财报的公司也超过了华尔街对第四季度收入的预期，“在很大程度上符合2024年的普遍预期，从而降低了即将发布的报告的风险。” Baird分析师补充道:“我们越来越感觉到，在未来几周的第四季度电话会议上，我们将听到Dentsply Sirona (XRAY.US)、Envista (NVST. ...

Johnson & Johnson (JNJ), Merck (MRK) and Boston Scientific (BSX) kicked off the year's biggest medical conference with a trio of splashy takeovers topping $3 billion in combined value.X Health care behemoth J&J is spending $2 billion to buy Ambrx (AMAM), Merck pledged to pay $680 million for Harpoon Therapeutics (HARP) and medtech player Boston Scientific (BSX) is coughing up $3.7 billion for Axonics (AXNX). Novartis (NVS) is also buying privately held Calypso Biotech for $250 million up front.The deals all ...